Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings

HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.

The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.

The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.

The research found that Therapy Arm 2 (ATT) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cyclespaclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to ACT as a standard treatment in the community. It has more peripheral neuropathy than ACT; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, APWP was superior to ACT in overall survival (OS).

In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.

    -- Daniel Von Hoff, M.D.
, Chief Scientific Officer:  The Complete Phase lb

       Clinical Trial: A Method to Accelerate New Agent Development


    -- Michael Teneriello, M.D., Co-Chair, Gynecologic Cancer Research

       Committee, US Oncology Research:  Results of a Phase II evaluation of

       nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-

       sensitive patients with recurrent ovarian, peritoneal, or fallopian

       tube cancer


    -- Patrick Timmins, III, M.D.:  Preliminary results of an open-label study

       to evaluate the efficacy and tolerability of aprepitant for the

       prevention of chemotherapy-induced nausea and vomiting associated with

       carboplatin-containing chemotherapy regimen in patients with ovarian

       cancer, primary peritoneal or fallopian tube carcinoma (stage I-IV) or

       papillary serous cancer of the uterus


    -- Craig Reynolds, M.D., Co-Chair Lung Cancer Research Committee:  An

       open-label, Phase II trial of nanoparticle albumin bound paclitaxel

       (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients

       with advanced non-squamous Non-Small Cell-Lung Cancer (NSCLC)


    -- Thomas Cartwright, M.D., Co-Chair, GI Cancer Research Committee:

       Results of a Phase II trial of cetuximab+XELIRI as first-line therapy

       of patients with advanced and/or metastatic colorectal cancer


    -- Craig Reynolds, M.D.:  A randomized phase 3 trial of gemcitabine with

       or without carboplatin in performance status 2 (PS2) patients (pts)

       with advanced (stage IIIB with pleural effusion or IV) Non-Small-Cell

       Lung Cancer (NSCLC)


    -- Robert Raju, M.D.:  Pemetrexed (P) in relapsed Small-Cell Lung Cancer

       (SCLC): Preliminary results of a Phase II trial


    -- Don Richards, M.D., Ph.D.:  The impact of shortened vitamin

       supplementation lead-in time before pemetrexed (P) in patients with

       relapsed Small-Cell Lung Cancer (SCLC)


    -- J.R.
 Hoverman, M.D., Medical Director of Managed Care, US Oncology:

       Assessment of medication safety in the outpatient setting


    -- Manuel Modiano, M.D.:  A phase I study of TPI 287, a third generation

       taxane, administered every 21 days in patients with advanced cancer


    -- Joanne Blum, M.D., Ph.D.:  Phase II study of eribulin mesylate (E7389)

       halichondrin b analog in patients with refractory breast cancer


    -- Alexander Spira, M.D.:  Phase II study of eribulin mesylate (E7389), a

       mechanistically novel inhibitor of microtubule dynamics, in patients

       with advanced Non-Small Cell-Lung Cancer (NSCLC)


    -- John Pippen, Jr., M.D., F.A.C.P.:  "A Historical Overview of the

       Treatment of Prostate Cancer and the Evolution of Bone Marrow

       Transplantation"


    -- Marcus Neubauer, M.D., Co-Chair:  Lung Cancer Research Committee: A

       clinical pathways project to promote evidence-based medicine in a large

       community oncology practice


    -- Domingo Perez, M.D.:  Phase II trial of carboplatin, weekly paclitaxel

       and biweekly bevacizumab in patients with unresectable stage IV

       melanoma


    -- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG

       006: Docetaxel and trastuzumab-based regimens improve DFS and OS over

       AC-T in node positive and high risk node negative HER2 positive early

       breast cancer patients: Quality of Life (QOL) at 36 months follow-up


    -- Dr. Alexander Spira:  Perifosine (P) an active agent in the treatment

       of patients with advanced sarcoma


    -- Dr. Alexander Spira:  iTARGET: A Phase II Trial to Assess the Response

       to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated

       Non-Small Cell-Lung Cancer (NSCLC) Tumors


    -- Dr. Hakan Kaya:  Survival outcomes for multiple myeloma over three

       decades: A Surveillance, Epidemiology, and End Results (SEER) analysis


    -- Dr. Hakan Kaya:  
Survival and secondary malignancy rates for adjuvant

       radiation therapy versus observation in stage I testicular seminoma: A

       Surveillance, Epidemiology, and End Results (SEER) analysis


    -- Dr. Kelly Pendergrass:  The Advanced Renal Cell Carcinoma Sorafenib

       (ARCCS) expanded access trial: safety and efficacy in patients (pts)

       with Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC)


    -- Roger Lyons, M.D.:  Tolerability and hematologic improvement assessed

       using three alternative dosing schedules of azacitidine in patients

       with myelodysplastic syndromes


    -- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology

       Research:  Pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell

       Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation

       Trial (RDT)


    -- Guru Sonpavde, M.D.:  Sunitinib malate is active and synergistic with

       cisplatin against human urothelial carcinoma in a preclinical model


About US Oncology Research

The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 528 physicians actively enrolling patients, 82 research sites, and is currently involved in 65 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer- fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About US Oncology, Inc.

US Oncology, headquartered in Houston, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and s upport to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.

According to the company's last quarterly earnings report, US Oncology is affiliated with 1077 physicians operating in 433 locations, including 90 radiation oncology facilities in 38 states.

CONTACT: Kimberly Rutherford of US Oncology, +1-832-601-6193,, or Elizabeth Vocke for US Oncology,+1-813-775-6202, Kimberly.Rutherford@usoncology.com Elizabeth.Vocke@hillandknowlton.com

Web site: http://www.usoncology.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Mich. , May 23, 2016 Diplomat Pharmacy, ... third annual Fellowship and Internship programs. The hands-on learning ... The full-time, paid Fellowship and ... Flint, Michigan . Fellows and interns are provided ... Flint at the Riverfront Residence ...
(Date:5/23/2016)... May 23, 2016 The World Health Organization (WHO) ... device to include adolescents aged 13 years, and above. Effective ... offered for adult and adolescent males in the 14 priority ... PrePex was the first male circumcision device to receive WHO ... Eddy Horowitz said: " The expanded ...
(Date:5/23/2016)... 23, 2016 The global  reprocessed ... billion by 2022, according to a new study by ... waste coupled with the lack of centralized support for ... drive the demand for reprocessed medical devices market. Additionally, ... to that of the original device is the high ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... , Roberta Jordan is a Certified Nurse Midwife who was born and ... and then went on to complete her masters degree from the University of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... services today announced a strategic partnership with Five9 (Nasdaq: FIVN), a leading ... one of Avaya’s largest Platinum Business Partners, is a leading provider of ...
(Date:5/24/2016)... ... 24, 2016 , ... New Brunswick, New Jersey: This year marks Children’s Specialized ... potential. To commemorate the anniversary, the hospital has themed the milestone “Hats Off” and ... Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in Piscataway, New Jersey. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health ... adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the shovels ... out the event photo slidehsow. , During the program, Richard H. Hart, MD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
Breaking Medicine News(10 mins):